[
  {
    "objectID": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy",
    "href": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy",
    "title": "The Acute Website",
    "section": "",
    "text": "Principle Investigator: Irene Zaghi, M.D.\nSupervisors:\n\nRussell E. Lewis, Pharm.D., University of Padua\nMonica Cricca, M.D., Ph.D., University of Bologna\nVittorio Sambri, M.D., Ph.D., Univeristy of Bologna\n\n\n\nJanuary 20, 2023"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\nImage: Irene Zaghi, M.D."
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-1",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-1",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\n\n(theuretzbacher2012?; Roberts2014?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-2",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-2",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\n\n(theuretzbacher2012?; Roberts2014?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#how-can-dosing-uncertainty-be-managed",
    "href": "slides/ACUTE_SLIDES.html#how-can-dosing-uncertainty-be-managed",
    "title": "The Acute Website",
    "section": "How can dosing uncertainty be managed?",
    "text": "How can dosing uncertainty be managed?\n\n\n\n\n\n\n\n(Roberts2014?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance",
    "href": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance",
    "title": "The Acute Website",
    "section": "Dosing uncertainty at the dawn of penicillin resistance",
    "text": "Dosing uncertainty at the dawn of penicillin resistance\n\n\n\n\n\n\n\n(schlichter_maclean47?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance-1",
    "href": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance-1",
    "title": "The Acute Website",
    "section": "Dosing uncertainty at the dawn of penicillin resistance",
    "text": "Dosing uncertainty at the dawn of penicillin resistance\n\n\n\n“It was felt that there was a need of some definite basis for determining adequate therapy for each specific infectious organism involved…”\n\n\n“Current methods in general use all depend on indirect comparisons (MICs, measurement of penicillin blood levels). In patients with more resistant organisms, it has not been demonstrated that this is the proper approach…”\n\n\n“…It occurred to us that a more satisfactory method of outlining adequate therapy in resistant organisms might be based on the action of the patient’s own serum during penicillin administration.”\n\n\n\n(schlichter_maclean47?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#serum-bactericidal-test-sbt",
    "href": "slides/ACUTE_SLIDES.html#serum-bactericidal-test-sbt",
    "title": "The Acute Website",
    "section": "Serum bactericidal test (SBT)",
    "text": "Serum bactericidal test (SBT)\n\n\n\n\n\n\n\n(clsi99?; zaghi_etal20?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#sbts-correlate-with-antibiotic-pkpd",
    "href": "slides/ACUTE_SLIDES.html#sbts-correlate-with-antibiotic-pkpd",
    "title": "The Acute Website",
    "section": "SBTs correlate with antibiotic PK/PD",
    "text": "SBTs correlate with antibiotic PK/PD\n\n\n\n\n\n\n\n(zaghi_etal20?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#potential-clinical-utility-of-sbts",
    "href": "slides/ACUTE_SLIDES.html#potential-clinical-utility-of-sbts",
    "title": "The Acute Website",
    "section": "Potential clinical utility of SBTs",
    "text": "Potential clinical utility of SBTs\n\nIndividual patient-level diagnostic meta-analysis (1947-2020)\n\n\n\n\n\nPrognostic performance similar or better than current susceptibility breakpoints\n\n\n(zaghi_etal20?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#sbt-advantages",
    "href": "slides/ACUTE_SLIDES.html#sbt-advantages",
    "title": "The Acute Website",
    "section": "SBT advantages",
    "text": "SBT advantages\n\n\nOnly microbiological test that accounts for both antibiotic PK and PD\nAccounts for protein binding changes\nCan detect synergistic or antagonistic antibiotic interactions"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#why-were-sbts-abandoned",
    "href": "slides/ACUTE_SLIDES.html#why-were-sbts-abandoned",
    "title": "The Acute Website",
    "section": "Why were SBTs abandoned?",
    "text": "Why were SBTs abandoned?\n\n\nInsufficient standardization despite published methods\n\nCLSI M21-A, last updated 1999\n\nPoor inter-laboratory reproducibility\nLabour-intensive to perform\nLack of perceived need after introduction of reliably bactericidal antibiotics in 1990s\n\n3rd generation cephalosporins, fluoroquinolones, carbapenems\n\nDelay in results reporting (48-72 hours with patients isolate)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#i-read-your-sbt-review-and-have-a-suggestion",
    "href": "slides/ACUTE_SLIDES.html#i-read-your-sbt-review-and-have-a-suggestion",
    "title": "The Acute Website",
    "section": "“I read your SBT review and have a suggestion…”",
    "text": "“I read your SBT review and have a suggestion…”\n\nUse continuously-monitored bloodculture systems Time-to-positivity (Tpos) to measure bactericidal activity\nConcept: The assay will measure time taken for a standardized bacterial inoculum to “grow through” the antimicrobial activity in the patient’s serum under defined conditions.\n\n\n\n\n\n\n\n\nA short Tpos would indicate inadequate antimicrobial activity and should predict a worse outcome\nA long Tpos is evidence of adequate antimicrobial activity and should predict a good outcome"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#blood-culture-tpos-measures-bacterial-inoculum-and-antimicrobial-pharmacokinetics",
    "href": "slides/ACUTE_SLIDES.html#blood-culture-tpos-measures-bacterial-inoculum-and-antimicrobial-pharmacokinetics",
    "title": "The Acute Website",
    "section": "Blood culture Tpos measures bacterial inoculum and antimicrobial pharmacokinetics",
    "text": "Blood culture Tpos measures bacterial inoculum and antimicrobial pharmacokinetics\n\n\nA “critical” Tpos result could be reported in &lt; 12 hours!\n\n\n\n\n\n\n\n\n(Kaltsas, Want, and Cohen 2005; jerwood2012?)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy-1",
    "href": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy-1",
    "title": "The Acute Website",
    "section": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy",
    "text": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy\n\n\n\n\n\n\n\n\nSpecific Aim# 1: Establish the quantitative relationship in vitro between Tpos and carbapenamase-producing Enterobacterales (CPE) and define antibiotic concentration-effect relationships\nSpecific Aim#2: Pilot observational clinical study in 20 septic patients undergoing treatment for CPE to explore how early Tpos results with “indicator” isolates correlate with individual antibiotic PK/PD targets"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-correlates-with-inoculum",
    "href": "slides/ACUTE_SLIDES.html#tpos-correlates-with-inoculum",
    "title": "The Acute Website",
    "section": "Tpos correlates with inoculum",
    "text": "Tpos correlates with inoculum\n\nK. pneumoniaeE. coliA. baumaniiP. aeruginosa\n\n\n\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nwp1 &lt;- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1 &lt;-ggplot(wp1, aes(x=inoculum, y=tpos, color=isolates, shape=diluent, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nkpc&lt;-fig1 + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\nplot(kpc)\n\n`geom_smooth()` using formula = 'y ~ x'\n\n\nWarning: Removed 75 rows containing non-finite values (`stat_smooth()`).\n\n\nWarning: Removed 75 rows containing missing values (`geom_point()`).\n\n\n\n\n\n\n\n\nlibrary (readxl)\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\necoliatcc_inoc &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/ecoliatcc_inoculum.xlsx\")\nfigecoli &lt;-ggplot(ecoliatcc_inoc, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\necoli&lt;- figecoli + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\nplot (ecoli)\n\n`geom_smooth()` using formula = 'y ~ x'\n\n\n\n\n\n\n\n\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\nabaumani &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/abaum_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nabaumi&lt;-ggplot(abaumani, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nabaumi2 &lt;-abaumi+ theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\nplot (abaumi2)\n\n`geom_smooth()` using formula = 'y ~ x'\n\n\n\n\n\n\n\n\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\npseudo &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/pseudo_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig2f &lt;-ggplot(pseudo, aes(x=inoculum, y=tpos, color=isolates, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\npsa &lt;-fig2f + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\nplot(psa)\n\n`geom_smooth()` using formula = 'y ~ x'\n\n\nWarning: Removed 14 rows containing non-finite values (`stat_smooth()`).\n\n\nWarning: Removed 14 rows containing missing values (`geom_point()`).\n\n\n\n\n\n\n\n\nR2 = 0.96-0.99"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-can-descriminate-between-susceptible-and-resistant-pathogens",
    "href": "slides/ACUTE_SLIDES.html#tpos-can-descriminate-between-susceptible-and-resistant-pathogens",
    "title": "The Acute Website",
    "section": "Tpos can descriminate between susceptible and resistant pathogens",
    "text": "Tpos can descriminate between susceptible and resistant pathogens\n\n\n\n\n\n\n\nKPC_B MIC 1.0 mg/L, KPC_NDM MIC > 256 mg/L; data fit by Loess"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#pharmacodynamic-relationship-of-tpos-against-k.-pneumoniae-atcc-700603-0.75-mgl",
    "href": "slides/ACUTE_SLIDES.html#pharmacodynamic-relationship-of-tpos-against-k.-pneumoniae-atcc-700603-0.75-mgl",
    "title": "The Acute Website",
    "section": "Pharmacodynamic relationship of Tpos against  K. pneumoniae ATCC 700603 (0.75 mg/L)",
    "text": "Pharmacodynamic relationship of Tpos against  K. pneumoniae ATCC 700603 (0.75 mg/L)\n\nCeftazidime-avibactam4:1 ratioFixed 4 mg/L\n\n\n\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7a &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\nfit_atcc &lt;- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\ncaz_avi_7b &lt;-read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpatcc_caz_avi_powderfix4.xlsx\")\nfit_atcc2 &lt;- drda(tpos ~ ctz_s, data=caz_avi_7b, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit_atcc,fit_atcc2, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\", legend_location=\"bottomright\", legend = c(\"CZA-AVI, 4:1 ratio\", \"CZA-AVI, fixed 4 mg/L\"))\n\n\n\n\n\n\n\nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7a &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\nfit_atcc &lt;- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit_atcc, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n23.87874\n19.31716\n28.44033\n\n\n0.25\n26.93812\n24.06902\n29.80723\n\n\n0.5\n30.38948\n29.11007\n31.66888\n\n\n0.75\n34.28302\n31.38838\n37.17767\n\n\n0.9\n38.67541\n33.84814\n43.50268\n\n\n0.95\n41.98020\n33.98412\n49.97627\n\n\n\n\n\n\n\n\n\n\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7a &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpatcc_caz_avi_powderfix4.xlsx\")\nfit7a &lt;- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit7a, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n8.099087\n7.038485\n9.159689\n\n\n0.25\n9.235833\n8.728989\n9.742676\n\n\n0.5\n10.532127\n10.149119\n10.915134\n\n\n0.75\n12.010361\n10.856802\n13.163921\n\n\n0.9\n13.696074\n11.685276\n15.706872\n\n\n0.95\n14.975851\n12.415855\n17.535846"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#inoculum-effects-observed-with-pd-relationship-measured-by-tpos",
    "href": "slides/ACUTE_SLIDES.html#inoculum-effects-observed-with-pd-relationship-measured-by-tpos",
    "title": "The Acute Website",
    "section": "Inoculum effects observed with PD relationship measured by Tpos",
    "text": "Inoculum effects observed with PD relationship measured by Tpos\n\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_hinc &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_caz_avi_com_hinoc.xlsx\")\nfithinc &lt;- drda(tpos ~ ctz_s, data=caz_avi_hinc, mean_function = \"loglogistic4\", max_iter = 1000)\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_6 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nfit_reginoc &lt;- drda(tpos ~ ctz_s, data=caz_avi_6, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fithinc, fit_reginoc, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\", legend = c(\"1x10^7\", \"1x10^4\"))"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "href": "slides/ACUTE_SLIDES.html#tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "title": "The Acute Website",
    "section": "Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs",
    "text": "Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#comparison-of-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#comparison-of-indicator-isolates",
    "title": "The Acute Website",
    "section": "Comparison of indicator isolates",
    "text": "Comparison of indicator isolates\n\nFigure 1: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#combination-therapy",
    "href": "slides/ACUTE_SLIDES.html#combination-therapy",
    "title": "The Acute Website",
    "section": "Combination therapy",
    "text": "Combination therapy"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#ceftazidime-avibactam-gentamicin",
    "href": "slides/ACUTE_SLIDES.html#ceftazidime-avibactam-gentamicin",
    "title": "The Acute Website",
    "section": "Ceftazidime-avibactam + gentamicin",
    "text": "Ceftazidime-avibactam + gentamicin"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#how-could-tpos-be-used-clinically",
    "href": "slides/ACUTE_SLIDES.html#how-could-tpos-be-used-clinically",
    "title": "The Acute Website",
    "section": "How could Tpos be used clinically",
    "text": "How could Tpos be used clinically"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#could-tpos-be-performed-with-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#could-tpos-be-performed-with-indicator-isolates",
    "title": "The Acute Website",
    "section": "Could Tpos be performed with “indicator” isolates?",
    "text": "Could Tpos be performed with “indicator” isolates?"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#references",
    "href": "slides/ACUTE_SLIDES.html#references",
    "title": "The Acute Website",
    "section": "References",
    "text": "References"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-can-discriminate-between-susceptible-and-resistant-pathogens",
    "href": "slides/ACUTE_SLIDES.html#tpos-can-discriminate-between-susceptible-and-resistant-pathogens",
    "title": "The Acute Website",
    "section": "Tpos can discriminate between susceptible and resistant pathogens",
    "text": "Tpos can discriminate between susceptible and resistant pathogens\n\nlibrary (ggplot2)\ntheme_set(theme_bw())\nceftaz &lt;- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_single/ceftazidime.csv\")\nggplot(ceftaz, aes(x=conc_s, y=tpos, color=isolate, shape=isolate)) + \n  geom_point(size=4, alpha = 0.7) + \n  geom_smooth(aes(linetype=isolate), method= loess, color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE ) +\nscale_x_log10(name=\"CAZ/AVI conc, mg/L\") +\nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,25)) \n\n`geom_smooth()` using formula = 'y ~ x'\n\n\n\n\n\n\n\nKPC_B MIC 1.0 mg/L, KPC_NDM MIC &gt; 256 mg/L; data fit by Loess"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#comparison-of-k.-pneumoniae-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#comparison-of-k.-pneumoniae-indicator-isolates",
    "title": "The Acute Website",
    "section": "Comparison of K. pneumoniae indicator isolates",
    "text": "Comparison of K. pneumoniae indicator isolates\n\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nkpca &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nkpcb &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nkpccatania &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpccatania_caz_avi_powder_4-1.xlsx\")\ncaz_avi_kfab &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kp_FAB_caz_avi_powder4-1.xlsx\")\nkpwt &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\ncaz_avi_kprad &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kp_PRAD_caz_avi_powder4-1.xlsx\")\nkpatcc &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\n\n## fit models for each of the isolates\nfitkpca &lt;- drda(tpos ~ ctz_s, kpca, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpcatcc &lt;- drda(tpos ~ ctz_s, kpatcc, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpcb &lt;- drda(tpos ~ ctz_s, kpcb, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpccatania &lt;- drda(tpos ~ ctz_s, kpccatania, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpwt &lt;- drda(tpos ~ ctz_s, kpwt, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkfab &lt;- drda(tpos ~ ctz_s, data=caz_avi_kfab, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkprad &lt;- drda(tpos ~ ctz_s, data=caz_avi_kprad, mean_function = \"loglogistic4\", max_iter = 1000)\n## plot all of the isolates together\np &lt;-plot(fitkpwt, fitkprad, fitkfab, fitkpcatcc, fitkpcb, fitkpca, fitkpccatania, base=\"10\", xlab = \"Ceftazidime-avibactam conc. (mg/L)\", ylab = \"Tpos\",cex = 0.9, legend_location=\"topleft\", legend = c(\"0.125 mg/L\", \"0.38 mg/L\",  \"0.5 mg/L\", \"0.75 mg/L\", \"1 mg/L\", \"2 mg/L\", \"16 mg/L\"))"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#at-a-standardized-inoculum-tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "href": "slides/ACUTE_SLIDES.html#at-a-standardized-inoculum-tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "title": "The Acute Website",
    "section": "At a standardized inoculum, Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs",
    "text": "At a standardized inoculum, Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs\n\n## Comparison of meropenem curves for ATCC and KPC_B strains adjusted for MIC\n\nlibrary (readxl)\nlibrary(drda)\nmero &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/ATCC_meropenem.xlsx\")\nmero2 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_meropenem.xlsx\")\nfit1 &lt;- drda(tpos ~ mero_mic, data=mero, mean_function = \"loglogistic4\", max_iter = 1000)\nfit2 &lt;- drda(tpos ~ mero_mic2, data=mero2, mean_function = \"loglogistic4\", max_iter = 1000)\n\n\n## Comparison of ceftazidime-avibactam curves for KPC-A and KPC_B strains adjusted for MIC\n\nlibrary (readxl)\nlibrary(drda)\nctz1 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nctz2 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nctz3 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/atcc_cazavi.xlsx\")\n\nNew names:\n• `` -&gt; `...7`\n\nfit3 &lt;- drda(tpos ~ ctz_mic, data=ctz1, mean_function = \"loglogistic4\", max_iter = 1000)\nfit4 &lt;- drda(tpos ~ ctz_mic, data=ctz2, mean_function = \"loglogistic4\", max_iter = 1000)\nfit5 &lt;- drda(tpos ~ ctz_mic, data=ctz3, mean_function = \"loglogistic4\", max_iter = 1000)\n\n\n\n# Comparison of tigecycline curves for KPC-A and KPC_B strains adjusted for MIC\n\ntig1 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpca_tig.xlsx\")\ntig2 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_tig.xlsx\")\nfittig1 &lt;- drda(tpos ~ tig_mic, data=tig1, mean_function = \"loglogistic4\", max_iter = 1000)\nfittig2 &lt;- drda(tpos ~ tig_mic, data=tig2, mean_function = \"loglogistic4\", max_iter = 1000)\n\n\n\n# Comparison of gentamicin curves for KPC-A and KPC_B strains adjusted for MIC\n\ngent1 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpca_gent.xlsx\")\ngent2 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_gent.xlsx\")\nfitgent1 &lt;- drda(tpos ~ gent_mic, data=gent1, mean_function = \"loglogistic4\", max_iter = 1000)\nfitgent2 &lt;- drda(tpos ~ gent_mic, data=gent2, mean_function = \"loglogistic4\", max_iter = 1000)\n\n\n# Colistin adjusted for MIC\n\ncol1 &lt;- read_excel(\"~/Desktop/ACUTEWEBSITE/datasets_single/kpcb_coli.xlsx\")\nfitco1 &lt;- drda(tpos ~ col_mic, data=col1, mean_function = \"loglogistic4\", max_iter = 1000)\n\n\n# plot all data\nplot (fit1, fit2, fit3, fit4, fit5, fittig1, fittig2, fitgent1, fitgent2, fitco1, xlab = \"Conc/MIC\", base=10, ylab = \"Tpos (hr)\", xlim =c(0,1000), legend_location=\"bottomright\", legend = c(\"MERO ATCC\", \"MERO KPC_B\", \"CZA-AVI KPC_A\", \"CZA-AVI KPC_B\", \"CZA-AVI ATCC\", \"Tig KPC_A\", \"TIG KPC_B\", \"GEN KPC_A\", \"GEN KPC_B\", \"Colistin KPC_B\"))\n\n\n\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-for-monitoring-antimicrobial-therapy",
    "href": "slides/ACUTE_SLIDES.html#tpos-for-monitoring-antimicrobial-therapy",
    "title": "The Acute Website",
    "section": "Tpos for monitoring antimicrobial therapy",
    "text": "Tpos for monitoring antimicrobial therapy"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-performed-using-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#tpos-performed-using-indicator-isolates",
    "title": "The Acute Website",
    "section": "Tpos performed using indicator isolates",
    "text": "Tpos performed using indicator isolates"
  },
  {
    "objectID": "Publications.html",
    "href": "Publications.html",
    "title": "Publications",
    "section": "",
    "text": "Is timing everything?\n\nA Bayesian meta-analysis of the prognostic and diagnostic utility of bloodculture time-to-positivity (TTP) and differential time-to positivity (DTP) for bloodstream infections\nClick here for the poster\nPresented at 2022 ESCMID Meeting, Lisbon\nAbstract #01824\n\n\n\n\n\nPharmacodynamics of ceftazidime-avibactam monotherapy and combination regimens against carbapenemase-producing Klebsiella pneumoniae measured by bloodculture system time to positivity (Tpos)\n Click here for the poster  Presented at 2023 ESCMID Meeting, Copenhagen Abstract #04032"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html",
    "href": "slides/ACUTE_SLIDES.html",
    "title": "The Acute Website",
    "section": "",
    "text": "Principle Investigator: Irene Zaghi, M.D.\nSupervisors:\n\nRussell E. Lewis, Pharm.D., University of Padua\nMonica Cricca, M.D., Ph.D., University of Bologna\nVittorio Sambri, M.D., Ph.D., Univeristy of Bologna\n\n\n\nJanuary 20, 2023"
  }
]